銀行貸款 小額借貸 線上貸款 汽車貸款 手機貸 瘋正妹 橘子影城 古蹟交流社 東森新聞手機板 東森新聞 港書館 super娛樂城 金鈦城娛樂城 信用版娛樂城 贏家娛樂城 WG娛樂城

The Aequs IPO enters its second day of subscription today, 4 December 2025. By the end of the first day, the issue was subscribed to 3.56 times overall. The bidding window is scheduled to close on December 5, 2025.
The Aequs IPO is a book-building issue of ?921.81 crore, consisting of a fresh issue of ?670 crore and an offer for sale (OFS) of ?251.81 crore. The price band is set between ?118 and ?124 per share.?
The basis of allotment will be finalised by December 8, 2025, and the tentative listing date on NSE and BSE is December 10, 2025.?
The book-running lead managers for the IPO are JM Financial Limited, IIFL Capital Services Limited, and Kotak Mahindra Capital Company Limited. At the same time, KFin Technologies Limited serves as the registrar for the issue.
[4-December-2025 17:00:00 hrs]
|
Investor Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
0.73 |
|
Non-Institutional Investors |
16.81 |
|
Retail Individual Investors (RIIs) |
32.92 |
|
Employees |
15.18 |
|
Total |
11.10 |
[3-December-2025 17:00:00 hrs]
|
Investor Category |
Subscription (Times) |
|
Qualified Institutional Buyers (QIBs) |
0.68 |
|
Non-Institutional Investors |
3.55 |
|
Retail Individual Investors (RIIs) |
12.16 |
|
Employees |
7.38 |
|
Total |
3.56 |
Utilisation of IPO Proceeds
The net proceeds from the fresh issue will be used to?
Aequs is the only precision component manufacturer operating within a single special economic zone in India to offer fully integrated, end-to-end production capabilities for the aerospace sector. This comprehensive integration distinguishes them from other contract manufacturers, which typically offer only selective or fragmented machining solutions.?
As of March 31, 2025, the company maintained one of the most extensive portfolios of aerospace components in the country.?
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.?
To read the RA disclaimer, please click here.